EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment burden on patients receiving intravitreal anti‐VEGF for wet age‐related macular degeneration

Erik Vinge iD, Tomas Bro iD

Acta Ophthalmologica · 2024-06 · 102 (4) · 478-482

DOI: 10.1111/aos.15783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 06.10.2023. Verfasst von Erik Vinge und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology Höglandssjukhuset Eksjö, Region Jönköping County, Eksjö, Sweden. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Intravitreal Injections, Vascular Endothelial Growth Factor A, Visual Acuity. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edwin Jordans Stiftelse för Oftalmologisk Forskning, Futurum - Akademin för Hälsa och Vård, Region Jönköpings läns.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to map the treatment burden for patients with wet age‐related macular degeneration (wAMD).

Method

Patients with ongoing treatment with anti‐VEGF for wAMD at a Swedish eye unit underwent a survey about the time spent receiving treatment, caregiver assistance, way of transportation, self‐rated vision and negative experiences associated with the treatment such as discomfort, anxiety or transportation problems. Information about current visual acuity, number of treatments and current treatment intervals were obtained from medical records.

Results

The study included 93 patients with an average age of 79.9 years, 68% were women. The average interval between treatments was 7.3 weeks, and 26% had active treatment in both eyes. On average, patients had to spend 2.7 h (2.4–2.9: 95% CI) per treatment and a caregiver assisted the patient in 58% of cases. Caregivers spent on average 2.6 h (2.5–2.8: 95% CI) per visit, and 19% needed to take time off work. The majority (91%) of patients did not experience any transportation problems associated with treatment. A multivariate logistic regression analysis showed a significantly lower odds ratio for discomfort with higher self‐rated vision and a significantly higher odds ratio for discomfort with longer treatment intervals.

Discussion

Anti‐VEGF treatment is an effective treatment for wAMD. However, the relatively short treatment intervals place a considerable burden on patients and their relatives regarding time. Although the patients in this study had to spend a lot of time to receive treatment, the majority did not experience any problems associated with treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsIntravitreal InjectionsVascular Endothelial Growth Factor AVisual AcuityWet Macular DegenerationAgedFemaleHumansMaleBevacizumabCaregiversCost of IllnessFollow-Up StudiesRanibizumabSurveys and QuestionnairesSweden

Stichwörter der Autor:innen

anti‐VEGFburdenpatient perspectivetreatmentwAMD

Substanzen

Angiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Autor:innen und Institutionen

  • Department of Ophthalmology Höglandssjukhuset Eksjö, Region Jönköping County, Eksjö, Sweden.
  • Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

ORCID-Profile: Erik Vinge, Tomas Bro

Förderung

  • Edwin Jordans Stiftelse för Oftalmologisk Forskning
  • Futurum - Akademin för Hälsa och Vård, Region Jönköpings läns

Zitieren

APA

Vinge, E., & Bro, T. (2024). Treatment burden on patients receiving intravitreal anti‐VEGF for wet age‐related macular degeneration. Acta Ophthalmologica, 102(4), 478-482. https://doi.org/10.1111/aos.15783

Vancouver

Vinge E, Bro T. Treatment burden on patients receiving intravitreal anti‐VEGF for wet age‐related macular degeneration. Acta Ophthalmologica. 2024;102(4):478-482. doi:10.1111/aos.15783

BibTeX
@article{Vinge2024,
  author = {Vinge, Erik and Bro, Tomas},
  title = {Treatment burden on patients receiving intravitreal anti‐VEGF for wet age‐related macular degeneration},
  journal = {Acta Ophthalmologica},
  year = {2024},
  volume = {102},
  number = {4},
  pages = {478--482},
  doi = {10.1111/aos.15783}
}
Kostenlos starten →